Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial
4 affiliations
- 1Department of Biological, Geological and Environmental Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy
- 2IBD Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- 3Department of Pharmacy and Health and Nutrition Sciences, University of Calabria, 87030 Rende, Cosenza, Italy
- 4Diadema Farmaceutici Srl, Via Gaetano Malasoma 28, 56121 Pisa, Italy
Abstract
Purpose: Oral iron supplementation is frequently limited by gastrointestinal side effects and reduced absorption associated with hepcidin-mediated regulation. This randomized, parallel-group, active-controlled study evaluated whether a reduced-dose alternate-day oral iron supplementation strategy could improve iron status in women with iron deficiency.
Methods: Sixty-six iron-deficient women of reproductive age (18–50 years; serum ferritin < 30 ng/mL) were randomized to receive, for 42 days, either micronized, dispersible ferric pyrophosphate providing 21 mg of elemental iron every 48 h combined with a daily gut microbiota modulator, or sucrosomial ferric pyrophosphate providing 30 mg of elemental iron per day. The primary endpoint was serum ferritin, while secondary endpoints included serum iron, transferrin, transferrin saturation (TSAT), total iron-binding capacity (TIBC), hemoglobin, and red blood cell count.
Results: Serum ferritin increased significantly over time in both groups (p < 0.001), with no significant differences between treatments. Comparable improvements were observed for serum iron, transferrin, TSAT, and TIBC, while hemoglobin remained stable throughout the study. Both interventions were generally well tolerated, with only mild transient gastrointestinal adverse events and no clinically relevant changes in inflammatory markers.
Conclusion: A reduced-dose alternate-day oral iron supplementation strategy achieved improvements in iron status comparable to standard daily supplementation despite lower cumulative iron exposure. These findings support the potential clinical relevance of physiologically informed low-dose iron supplementation strategies in women with iron deficiency.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00394-026-04139-9.
Related
- Efficacy of ferrous fumarate with elemental iron 60 mg alternate-day, 120 mg alternate-day vs 60 mg once a day therapy in the treatment of iron deficiency anaemia: study protocol for a randomised controlled trial
- Effects of extremely low-volume high-intensity interval training combined with iron supplementation versus iron supplementation alone on postural control in young women with iron deficiency anemia: a randomized controlled trial.
- Identifying Iron Deficiency and Opportunities for IV Iron Supplementation in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Cohort Study
- Skin Lightening and Evenness Effects of Oral Supplementation With S‐Acetyl Glutathione in Comparison With Reduced Glutathione: A Double‐Blind, Placebo‐Controlled Clinical Trial
- Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial
BibTeX
@article{valerii2026reduceddose,
title = {{Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial}},
author = {Maria Chiara Valerii and Nikolas Kostantine Dussias and Anna Perri and Renato Spigarelli and Alberto Bernacchi and Fernando Rizzello and Gianluigi Magri and Paolo Gionchetti and Enzo Spisni},
journal = {European Journal of Nutrition},
year = {2026},
month = oct,
doi = {10.1007/s00394-026-04139-9},
url = {https://doi.org/10.1007/s00394-026-04139-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Reduced-dose alternate-day oral iron supplementation in women with iron deficiency: a randomized controlled trial
AU - Maria Chiara Valerii
AU - Nikolas Kostantine Dussias
AU - Anna Perri
AU - Renato Spigarelli
AU - Alberto Bernacchi
AU - Fernando Rizzello
AU - Gianluigi Magri
AU - Paolo Gionchetti
AU - Enzo Spisni
PY - 2026
DA - 2026/10/25
JO - European Journal of Nutrition
DO - 10.1007/s00394-026-04139-9
UR - https://doi.org/10.1007/s00394-026-04139-9
AB - Purpose: Oral iron supplementation is frequently limited by gastrointestinal side effects and reduced absorption associated with hepcidin-mediated regulation. This randomized, parallel-group, active-controlled study evaluated whether a reduced-dose alternate-day oral iron supplementation strategy could improve iron status in women with iron deficiency. Methods: Sixty-six iron-deficient women of reproductive age (18–50 years; serum ferritin < 30 ng/mL) were randomized to receive, for 42 days, either micronized, dispersible ferric pyrophosphate providing 21 mg of elemental iron every 48 h combined with a daily gut microbiota modulator, or sucrosomial ferric pyrophosphate providing 30 mg of elemental iron per day. The primary endpoint was serum ferritin, while secondary endpoints included serum iron, transferrin, transferrin saturation (TSAT), total iron-binding capacity (TIBC), hemoglobin, and red blood cell count. Results: Serum ferritin increased significantly over time in both groups (p < 0.001), with no significant differences between treatments. Comparable improvements were observed for serum iron, transferrin, TSAT, and TIBC, while hemoglobin remained stable throughout the study. Both interventions were generally well tolerated, with only mild transient gastrointestinal adverse events and no clinically relevant changes in inflammatory markers. Conclusion: A reduced-dose alternate-day oral iron supplementation strategy achieved improvements in iron status comparable to standard daily supplementation despite lower cumulative iron exposure. These findings support the potential clinical relevance of physiologically informed low-dose iron supplementation strategies in women with iron deficiency. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00394-026-04139-9.
SN - 1436-6207
SN - 1436-6215
ER -